Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor β gene

Haematologica

Volumn 92, Issue 2, 2007, Pages

  Walz, Christoph ^a   Metzgeroth, Georgia ^a   Haferlach, Claudia ^b   Schmitt Graeff, Annette ^c   Fabarius, Alice ^a   Hagen, Volker ^d   Prümmer, Otto ^e   Rauh, Stefan ^f   Hehlmann, Rüdiger ^a   Hochhaus, Andreas ^a   Cross, Nicholas C P ^g   Reiter, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d ST JOHANNES HOSPITAL   (Germany)

^e Klinikum Kempten Oberallgau   (Germany)

^f Hospital Princesse Marie Astrid   (Luxembourg)

^g UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

GIT2; GPIAP1; Imatinib; PDGFRB; PRKG2

Indexed keywords

ANKYRIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; ANTINEOPLASTIC AGENT; GIT2 PROTEIN, HUMAN; GPIAP1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANAMNESIS; ARTICLE; CASE REPORT; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHRONIC DISEASE; FEMALE; FUSION GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MALE; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; CHROMOSOME 5; CHROMOSOME BANDING PATTERN; GENE TRANSLOCATION; GENETICS; MIDDLE AGED;

AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; GTPASE-ACTIVATING PROTEINS; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 33947543336     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10980     Document Type: Article

References (47)

1. Cross NCP, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16:1207-12.
2. Giles FJ, Cortes JE, Kantarjian HM. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med 2005;5:615-23.
3. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
4. Willis TG, Jadayel DM, Coignet LJ, Abdul-Rauf M, Treleaven JG, Catovsky D, et al. Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood 1997;90:2456-64.
5. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 2003;102:1443-8.
6. Vizmanos JL, Novo FJ, Roman JP, Baxter EJ, Lahortiga I, Larrayoz MJ, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 2004;64:2673-6.
7. Reiter A, Walz C, Cross NCPC. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Current Drug Targets 2007 (in press).
8. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
9. Delaval B, Letard S, Lelievre H, Chevrier V, Daviet L, Dubreuil P, et al. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome. Cancer Res 2005; 65: 7231-40.
10. Delaval B, Lelievre H, Birnbaum D. Myeloproliferative disorders: the centrosome connection. Leukemia 2005;19:1739-44.
11. Kramer A. Centrosome aberrations - hen or egg in cancer initiation and progression? Leukemia 2005; 19: 1142-4.
12. Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004;5:287-98.
13. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
14. Abe A, Emi N, Tanimoto M, Terasaki H, Marunouchi T, Saito H. Fusion of the platelet-derived growth factor receptor β to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 1997; 90: 4271-7.
15. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntington interacting protein 1 to platelet-derived growth factor beta receptor (PDGFβR) in chronic myelomonocytic leukemia with t(5;7) (q33; q11.2). Blood 1998; 91:4419-26.
16. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor β in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 2000; 60:3592-8.
17. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor P receptor in chronic myelo-monocytic leukemia. Blood 2001;98: 2518-25.
18. Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003;102:4187-90.
19. Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F, et al. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res 2004; 64:2649-51.
20. Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, et al. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14) (q33;q32). Leukemia 2005; 19:27-30.
21. Grand FH, Burgstaller S, Kuhr T, Baxter EJ, Webersinke G, Thaler J, et al. p53-binding protein 1 is fused to the platelet-derived growth factor receptor β in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 2004; 64:7216-9.
22. Rosati R, La SR, Luciano L, Gorello P, Matteucci C, Pierini V, et al. TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukemia 2006;20: 1623-4.
23. Rosati R, La Starza R, Bardi A, Luciano L, Matteucci C, Pierini V, et al. PDGFRB fuses to TPM3 in the t(1;5)(q23;q33) of chronic eosinophilic leukemia and to NDE1 in the t(5;16)(q33;p13) of chronic myelomonocytic leukemia. Haematologica 2006;91 Suppl 1:214.
24. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002;11:1391-7.
25. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-14.
26. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, et al. Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent. Proc Natl Acad Sci USA 2006;103:8078-83.
27. Mosavi LK, Minor DL, Jr., Peng ZY. Consensus-derived structural determinants of the ankyrin repeat motif. Proc Natl Acad Sci USA 2002; 99: 16029-34.
28. Batchelor AH, Piper DE, de la Brousse FC, McKnight SL, Wolberger C. The structure of GABPα/β: an ETS domain- ankyrin repeat heterodimer bound to DNA. Science 1998;279:1037-41.
29. Gessler M, Klamt B, Tsaoussidou S, Ellis JA, Luzio JP. The gene encoding the GPI-anchored membrane protein p137GPI (M11S1) maps to human chromosome 11p13 and is highly conserved in the mouse. Genomics 1996;32:169-70.
30. Grill B, Wilson GM, Zhang KX, Wang B, Doyonnas R, Quadroni M, et al. Activation/division of lymphocytes results in increased levels of cytoplasmic activation/proliferation-associated protein-1: prototype of a new family of proteins. J Immunol 2004;172:2389-400.
31. Wang B, David MD, Schrader JW. Absence of caprin-1 results in defects in cellular proliferation. J Immunol 2005;175:4274-82.
32. Premont RT, Claing A, Vitale N, Perry SJ, Lefkowitz RJ. The GIT family of ADP-ribosylation factor GTPase-activating proteins. Functional diversity of GIT2 through alternative splicing. J Biol Chem 2000;275:22373-80.
33. Paris S, Longhi R, Santambrogio P, de C, I. Leucine-zipper-mediated homo- and hetero-dimerization of GIT family p95-ARF GTPase-activating protein, PIX-, paxillin-interacting proteins 1 and 2. Biochem J 2003;372:391-8.
34. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006;86:1-23.
35. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, et al. The t(3;5) (q25.1; q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12:265-75.
36. Borkhardt A, Bojesen S, Haas OA, Fuchs U, Bartelheimer D, Loncarevic IF, et al. The human GRAF gene is fused to MLL in a unique t(5;11) (q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA 2000; 97:9168-73.
37. Taki T, Kano H, Taniwaki M, Sako M, Yanagisawa M, Hayashi Y. AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13q23). Proc Natl Acad Sci USA 1999;96:14535-40.
38. Jaiu RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K, et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 2001;98:1264-7.
39. Yagasaki F, Jinnai I, Yoshida S, Yokoyama Y, Matsuda A, Kusumoto S, et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromosomes Cancer 1999; 26:192-202.
40. Reiter A, Saussele S, Grimwade D, Wiemels JL, Segal MR, Lafage-Pochitaloff M, et al. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer 2003;36:175-88.
41. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352: 1529-38.
42. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998; 92: 1735-42.
43. Zhang JG, Goldman JM, Cross NC. Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. Br J Haematol 1995;90:138-46.
44. Robyn J, Lemery S, McCoy JP, Kubofcik J, Kim YJ, Pack S, et al. Multilineage involvement of the fusion gene in patients with FIPlLl/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006;132:286-92.
45. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006; 19:595-615.
46. Walz C, Curtis C, Schnittger S, Schultheis B, Metzgeroth G, Schoch C, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4) (q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006; 45:950-6.
47. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662-7.